FDA Drug Safety Communication: Updated Risk Evaluation and Mitigation Strategy (REMS) to Restrict Access to Rosiglitazone-containing Medicines including Avandia, Avandamet, and Avandaryl
Links shared publicly online about this topic.
- 284total visits
FDA Drug Safety Communication: Updated Risk Evaluation and Mitigation Strategy (REMS) to Restrict Access to Rosiglitazone-containing Medicines including Avandia, Avandamet, and Avandaryl
fda.gov —
The U.S. Food and Drug Administration (FDA) is informing the public of new restrictions to the prescribing and use of rosiglitazone-containing medicines.
View full resource at fda.gov
Tags: Diabetes Type 2 Medication, Diabetes Medication, Drug, FDA, Avandia, Safety, Medical
Most Recently Shared on May 18, 2011 at 7:55 pm By:
Updated Risk Evaluation & Mitigation Strategy to Restrict Access to Rosiglitazone-containing Medicines (FDA) http://1.usa.gov/lwECEi
Advertisement
